Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Glaukos Corporation

GKOSNYSEEQUITYCurrent

Changes in Beneficial Ownership

Filed Mar 27, 2026Accepted Mar 27, 2026, 8:33 PM EDTFiling CIK 1644557Accession 0001644557-26-000018
Share

Structured filing — 4

form4-03282026_120327.xml

Open full document ↗

Filing details

Report period
2026-03-25
Issuer
GLAUKOS Corp
Issuer CIK
0001192448
Trading symbol
GKOS

Reporting owner 1

Name
Burns Thomas William
Reporting owner CIK
0001644557
Relationship
Director · Officer
Officer title
CHAIRMAN & CEO
Address
C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656

Non-derivative transactions

Non-derivative transactions · 2 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-03-25A · Form 49,380[F1]A0249,087[F2]D
Common Stock2026-03-25A · Form 414,184[F3]A0263,271[F4]D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Non-derivative holdings

Non-derivative holdings · 5 reported rows
SecurityAmount ownedOwnershipNature of ownership
Common Stock961,285IThrough the Burns Family Trust
Common Stock238,107IThrough the Burns Annuity Trust
Common Stock120,000IThrough the Burns Charitable Remainder Trust
Common Stock100,000IThrough the Thomas W. Burns Irrevocable Trust
Common Stock100,000IThrough the Janet M. Burns Irrevocable Trust
Table key
I
Indirect

Derivative transactions

Derivative transactions · 3 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)55.182026-03-25A · Form 418,933[F5]A18,933[F6]2032-03-24Common Stock18,933105,195D
Stock Option (Right to Buy)48.462026-03-25A · Form 4110,254[F7]A110,2542026-03-252033-03-22Common Stock110,254110,254D
Stock Option (Right to Buy)109.602026-03-25A · Form 498,474A98,474[F8]2036-03-25Common Stock98,47498,474D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets. 50% of the number of shares of common stock reported herein will vest and be delivered in March 2026, and the remaining 50% will vest and be delivered in December 2026.↩ 1
F2
Includes 68,779 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1
F3
Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 14, 2024, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares reported herein consists of the portion of the award that was deemed earned based upon the achievement of the operational target. 100% of the number of shares of common stock reported herein will vest and be delivered in March 2026.↩ 1
F4
Includes 82,963 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1
F5
Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.↩ 1
F6
50% of the portion of the option reported herein will vest and become exercisable in March 2026. 50% of the portion of the option reported herein will vest and become exercisable in December 2026.↩ 1
F7
Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.↩ 1
F8
This option was granted on March 25, 2026 and has a four-year vesting schedule in which 25% vests on the first anniversary of the grant date and the remainder vests in equal monthly installments for 36 months thereafter, such that the stock option vests in full on the four-year anniversary of the grant date.↩ 1

Signature 1

Signed
Diana Scherer, Attorney-in-Fact
Date
2026-03-27

Company context

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding GLAUKOS CorpNov 16, 2026
  2. Regulation FD DisclosureNov 6, 2026
  3. 10-Q filingOct 28, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureOct 28, 2026
  5. 144 filingSep 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.